Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Alembic Pharmaceuticals is a Vadodara-based pharma company with a branded generics business in India (strong in anti-infectives, gastro, gynaecology — legacy brand Azithral among its largest) and a substantial US generics business built on oral solids, injectables and ophthalmics from multiple USFDA plants. It also produces APIs for captive use and merchant sale. Revenue is split across India branded, US generics and API/international, with US price erosion and new launches the key swing factors.
A mid-cap Indian pharma with a century-old domestic franchise and meaningful US generics exposure.
Alembic Pharmaceuticals Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Alembic Pharmaceuticals Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 34.33 | 29.68 | 31.33 |
| Book value / share (₹) | 288.42 | 264.03 | 245.12 |
| Return on equity | 11.8% | 11.2% | 12.8% |
| Return on capital employed | 13.0% | 13.6% | 13.2% |
| Operating margin | 10.9% | 10.9% | 10.6% |
| Net margin | 9.1% | 8.7% | 9.9% |
| EBITDA | ₹1,118 Cr | ₹1,008 Cr | ₹933 Cr |
| Free cash flow | ₹348 Cr | ₹-476 Cr | ₹476 Cr |
| Total debt | ₹1,361 Cr | ₹1,196 Cr | ₹430 Cr |
| Debt to equity | 0.24 | 0.23 | 0.09 |
| Interest coverage | 8.5 | 9.3 | 11.8 |
| Current ratio | 1.75 | 1.69 | 2.12 |
| Shares outstanding | 19,65,50,000 | 19,65,50,000 | 19,65,65,000 |
Open the full income statement, balance sheet and cash flow for APLLTD →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.